Analgesic Efficacy of Maxigesic in Breast Cancer Surgery

Launched by YONSEI UNIVERSITY · Dec 15, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of a medication called Maxigesic for managing pain in women undergoing breast cancer surgery. Maxigesic combines two pain relievers: acetaminophen and ibuprofen. The goal is to provide good pain control while also being gentle on the immune system, which is important for recovery after surgery. Participants in this study will receive Maxigesic along with standard pain management that includes opioids.

To be eligible for this trial, women aged 20 to 70 who are scheduled for breast cancer surgery may participate, provided they have a certain level of health (classified as ASA 1 to 3). However, those with more serious health issues or allergies to the medications being tested cannot join. If you decide to participate, you can expect close monitoring by the medical team to ensure your comfort and safety during the study.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patient aged 20 to 70 years with ASA classification 1 to 3 undergoing breast cancer surgery (cancer resection or reconstruction)
• Exclusion Criteria:
• • ASA classification 4/ allergy to acetaminophen, NSAIDs, opioid/ severe liver or renal dysfunction/ pregnancy